RxDoctor Payments Data

Ziad Allos, MD

Family Medicine · la Mesa, CANPI 1215243092

Payments from drug & device makers

$1,158in general payments, 2019–2025

Across 59 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$336
  • Exact Sciences$158
  • AstraZeneca$158
  • AbbVie$144
  • Novo Nordisk$86
  • Lilly USA, LLC$65
  • plus $210 from 10 others

What the payments were for

  • Food & beverage$1,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,158 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$199,747
Medicare patients
436
Services billed
2,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$99,773
JardianceEmpagliflozin75$74,134
RybelsusSemaglutide24$43,756
EliquisApixaban41$40,982
MounjaroTirzepatide19$24,084
FarxigaDapagliflozin Propanediol31$23,791
TradjentaLinagliptin19$18,271
JanuviaSitagliptin Phosphate29$16,882
MyrbetriqMirabegron11$9,180
LinzessLinaclotide11$7,016
Celecoxib41$4,439
Atorvastatin Calcium396$3,357
Rosuvastatin Calcium176$3,329
Losartan Potassium227$2,651
Tamsulosin Hcl154$2,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$86$143,52988 claims
Boehringer IngelheimJardiance, Tradjenta$20$92,40594 claims
PfizerEliquis$336$40,98241 claims
Lilly USA, LLCMounjaro$65$24,08419 claims
AstraZenecaFarxiga$158$23,79131 claims
MerckJanuvia$20$16,88229 claims
AbbVieLinzess, Synthroid$144$7,64730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →